Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | ADK | P55263 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 3/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634334 | 0.82 | KDM4E (0.72) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL29140136 | 0.81 | ALDH1A1 (0.70) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL722191 | 0.80 | NISCH (0.78) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL862114 | 0.78 | NISCH (0.75) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL17303458 | 0.78 | KDM4E (0.77) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL1060312 | 0.76 | KDM4E (1.00) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL5941063 | 0.75 | KDM4E (0.72) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL7383120 | 0.75 | KDM4E (0.72) | KDM4EALDH1A1NISCHMTORADK | |
| SCHEMBL27972616 | 0.75 | KDM4E (0.96) | KDM4EALDH1A1NISCHMTORADK | |
| Hydrochloric Acid SCHEMBL3895818 | 0.75 | KDM4E (0.96) | KDM4EALDH1A1NISCHMTORADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | disclosed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | disclosed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-1294367-B1 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | PROCTER & GAMBLE (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060193790-A1 | Promoting whole body health | THE PROCTER & GAMBLE COMPANY | 2006-08-31 | — | — | US | disclosed |
| EP-1226819-B1 | INHIBITOR FOR 20-HETE-YIELDING ENZYME | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | UNIVERSITY OF MASSACHUSETTS (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005007107-A2 | HISTAMINE AND CCK2/GASTRIN RECEPTOR BLOCKADE IN THE TREATMENT OF ACID-PEPTIC DISEASE AND CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1294367-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | The Procter & Gamble Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-4465841-A | ANTISECRETORY, ANTIULCER AGENTS | INSTITUTO DE ANGELI S.P.A. (IT) | 1984-08-14 | — | — | US | disclosed |
| US-4465841-A | ANTISECRETORY, ANTIULCER AGENTS | INSTITUTO DE ANGELI S.P.A. (IT) | 1984-08-14 | — | — | US | disclosed |
| US-4465841-A | ANTISECRETORY, ANTIULCER AGENTS | INSTITUTO DE ANGELI S.P.A. (IT) | 1984-08-14 | — | — | US | disclosed |
| EP-0094727-A2 | Substituted heterocyclyl phenylformamidines, processes for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1983-11-23 | — | — | EP | disclosed |
| US-4386099-A | GASTROINTESTINAL DISORDERS, ULCERS | ISTITUTO DE ANGELI S.P.A. (IT) | 1983-05-31 | — | — | US | disclosed |
| US-4386099-A | GASTROINTESTINAL DISORDERS, ULCERS | ISTITUTO DE ANGELI S.P.A. (IT) | 1983-05-31 | — | — | US | disclosed |
| US-4386099-A | GASTROINTESTINAL DISORDERS, ULCERS | ISTITUTO DE ANGELI S.P.A. (IT) | 1983-05-31 | — | — | US | disclosed |
| EP-0053407-A2 | New imidazolylphenyl amidines, processes for their preparation and their pharmaceutical use, and intermediates of preparation | ISTITUTO DE ANGELI S.p.A. (IT) | 1982-06-09 | — | — | EP | disclosed |
| EP-0053407-A2 | New imidazolylphenyl amidines, processes for their preparation and their pharmaceutical use, and intermediates of preparation | ISTITUTO DE ANGELI S.p.A. (IT) | 1982-06-09 | — | — | EP | disclosed |
| EP-0053407-A2 | New imidazolylphenyl amidines, processes for their preparation and their pharmaceutical use, and intermediates of preparation | ISTITUTO DE ANGELI S.p.A. (IT) | 1982-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193790-A1 | Promoting whole body health | IFNG, TNF, TLR6 | KDM4E 4204/4885ALDH1A1 4304/4885NISCH 3039/4885 |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | HRH2, CCKBR, GRPR | KDM4E 4168/4885ALDH1A1 2969/4885NISCH 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.